MRKClinical Trials•businesswire•September 11, 2025 at 10:45 AM

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

Sentiment:Positive (70)

Summary

(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 11, 2025 by businesswire